Cell cycle arrest and apoptosis are early events in radiosensitization of EWS::FLI1+ Ewing sarcoma cells by Mithramycin A.

PURPOSE The oncogenic fusion protein EWS::FLI1 is an attractive therapeutic target in Ewing sarcoma (ES). Mithramycin A (MithA) is a potent and specific inhibitor of EWS::FLI1 that can selectively radiosensitize ES cells through transcriptional inhibition of DNA double-strand break (DSB) repair. Here, we evaluate temporal changes in cell cycle progression and apoptosis in ES cells treated with MithA and/or ionizing radiation (RTx), testing the hypothesis that combining MithA with ionizing radiation would synergistically impair cell cycle progression and enhance apoptotic elimination to a greater extent than either agent alone. MATERIALS AND METHODS Four EWS::FLI1+ Ewing sarcoma cell lines TC-71, RD-ES, SK-ES-1, and A673, and one EWS::Erg cell line (CHLA-25) were exposed to 10nM MithA or vehicle and followed twenty-four hours later by exposure to 2Gy x-radiation or sham irradiation. Reactive oxygen species (ROS) activity was evaluated by cytometric assay, and assay of antioxidant gene expression by RT-qPCR. Cell cycle changes were evaluated by flow cytometry of nuclei stained with propidium iodide. Apoptosis was assessed by cytometric assessment of Caspase-3/7 activity and by immunoblotting of PARP-1 cleavage. Radiosensitization was evaluated by clonogenic survival assay. Proliferation (EdU) and apoptosis (TUNEL) were evaluated in SK-ES-1 xenograft tumors following pre-treatment with 1mg/kg MithA, followed 24 hours later by a single 4Gy fraction of x-radiation. RESULTS MithA treated cells showed reduced levels of ROS, and was associated with increased expression of antioxidant genes SOD1, SOD2 and CAT. It nonetheless induced persistent G0/G1 arrest and progressive increase of the sub-G1 fraction, suggesting apoptotic degeneration. In vitro assays of Caspase-3/7 activity and immunoblotting of Caspase-3/7 dependent cleavage of PARP-1 indicated that apoptosis began as early as 24-hours after MithA exposure, reducing clonogenic survival. Tumors from xenograft mice treated with either radiation alone, or in combination with MithA showed significant reduction of tumor cell proliferation, while apoptosis was significantly increased in the group receiving combination of MithA and RTx. CONCLUSIONS Taken together, our data show that the anti-proliferative and cytotoxic effects of MithA are the prominent components of radiosensitization of EWS::FLI1+ Ewing sarcoma, rather than the result of acutely enhanced ROS levels.

[1]  Xianqun Fan,et al.  Promoting reactive oxygen species generation: a key strategy in nanosensitizer-mediated radiotherapy. , 2021, Nanomedicine.

[2]  T. Damron,et al.  Mithramycin A radiosensitizes EWS:Fli1+ Ewing sarcoma cells by inhibiting double strand break repair. , 2020, International journal of radiation oncology, biology, physics.

[3]  Gabrielle E Foxa,et al.  Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor , 2020, EMBO molecular medicine.

[4]  Chuong D. Hoang,et al.  UHRF1 is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  D. Venzon,et al.  Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters , 2019, Molecular Pharmacology.

[6]  P. Houghton,et al.  Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force , 2019, F1000Research.

[7]  Zhongmei Zhou,et al.  Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1 , 2018, Scientific Reports.

[8]  S. Lessnick,et al.  Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma , 2017, PloS one.

[9]  L. Helman,et al.  A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript , 2017, Cancer Chemotherapy and Pharmacology.

[10]  Hongmei Gao,et al.  Mithramycin inhibits epithelial-to-mesenchymal transition and invasion by downregulating SP1 and SNAI1 in salivary adenoid cystic carcinoma , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[11]  Jingxi Ma,et al.  Prdx6 Upregulation by Curcumin Attenuates Ischemic Oxidative Damage via SP1 in Rats after Stroke , 2017, BioMed research international.

[12]  A. Astudillo,et al.  Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma , 2016, Oncotarget.

[13]  T. Das,et al.  Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin. , 2015, Translational research : the journal of laboratory and clinical medicine.

[14]  Mark Girolami,et al.  EWS-FLI1 employs an E2F switch to drive target gene expression , 2015, Nucleic acids research.

[15]  Eun-Sun Choi,et al.  Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer , 2014, Scientific Reports.

[16]  H. Kovar Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy , 2014, Expert opinion on therapeutic targets.

[17]  P. Meltzer,et al.  Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer , 2013, Genome research.

[18]  S. Chopde Fortified foods for combat with malnutrition , 2013 .

[19]  S. Blacher,et al.  Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors , 2013, PloS one.

[20]  K. Ross,et al.  The Biology of Ewing Sarcoma , 2013, ISRN oncology.

[21]  S. Safe,et al.  Mithramycin A Inhibits Myeloid Cell Leukemia-1 to Induce Apoptosis in Oral Squamous Cell Carcinomas and Tumor Xenograft through Activation of Bax and Oligomerization , 2013, Molecular Pharmacology.

[22]  K. Ishige,et al.  Neuroprotective effect of mithramycin against endoplasmic reticulum stress-induced neurotoxicity in organotypic hippocampal slice cultures , 2011, Neuropharmacology.

[23]  Qing-Rong Chen,et al.  Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. , 2011, Journal of the National Cancer Institute.

[24]  Kiyoko Kato,et al.  Low‐dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin‐3 in gynecologic cancers , 2010, Cancer science.

[25]  P. Meltzer,et al.  A Molecular Function Map of Ewing's Sarcoma , 2009, PloS one.

[26]  Nicolò Riggi,et al.  The Biology of Ewing sarcoma. , 2007, Cancer letters.

[27]  S. Elmore Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[28]  A. I. Rojo,et al.  Regulation of heme oxygenase-1 gene expression through the phosphatidylinositol 3-kinase/PKC-zeta pathway and Sp1. , 2006, Free radical biology & medicine.

[29]  G. Laurent,et al.  Mithramycin A activates Fas death pathway in leukemic cell lines , 2006, Apoptosis.

[30]  Y. Iwamoto,et al.  Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors , 2005, International journal of cancer.

[31]  Y. Iwamoto,et al.  Transactivation of cyclin E gene by EWS‐Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells , 2005, International journal of cancer.

[32]  T. Cotter,et al.  The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) , 2004, British Journal of Cancer.

[33]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[34]  K. Tanaka,et al.  Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G 1 regulatory genes , 2001, British Journal of Cancer.

[35]  L. Kuhns,et al.  Effects of radiation therapy on growing long bones. , 1976, AJR. American journal of roentgenology.

[36]  A. Cheong,et al.  K(v)1.5 potassium channel gene regulation by Sp1 transcription factor and oxidative stress. , 2007, American journal of physiology. Heart and circulatory physiology.